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Predictors of Staphylococcus aureus pneumonia 
associated with human immunodeficiency virus 
infection 
M. TUMBARELLO*, E. TACCONELLI, M. B. LUCIA, R. CAUDAAND L. ORTONA 
Department of Infectious Diseases, Catholic University, Rome, Italy 
This study is based on a retrospective logistic regression analysis of all human immunodeficiency virus 
(HIV)-infected patients with Staphylococcus aureus pneumonia (SAP) admitted to the Department of 
Infectious Diseases, Catholic University, Rome, Italy between January 1986 and December 1994. Nineteen 
patients with 24 episodes of SAP were enrolled in the study. A control group of 38 HIV-infected patients 
without pneumonia was included. The attack rate of SAP was 8.31/1000 HIV-related hospital admissions and 
the frequency, out of the total number of bacterial pneumonia observed in the study period, was 16% (24 of 
154 patients). The large majority of SAP was community acquired. On the univariate analysis, intravenous 
drug abuse (IVDA) (P=O.O2), history of previous Pneumocystis carinii pneumonia (PCP) (P=O.O3) and 
cirrhosis (P=O.O3) were significant risk factors for SAP. In addition, IVDA and previous PCP were 
independent risk factors on multivariate analysis. All patients presented with fever associated with cough 
(74%), chest pain (26%) or shortness of breath (37%). Chest X-ray documented lobar pneumonia (78%), 
predominantly in the lower lobes, consolidation with cavitation (1 l%), and interstitial-nodular infiltrates 
(11%). Pleural effusion was present in 31% of patients. The response to therapy was favourable in 79% of 
patients. Recurrence occurred in 26% and death occurred in 21% of patients. Death was significantly 
associated with the low level (450 mm- ‘) of circulating T CD4+ cells (P=O.O3) and the recurrence of 
pneumonia (P=O.O3). In conclusion, the present study indicates that 5’. aureus is an important aetiologic agent 
of bacterial pneumonia in HIV-infected patients, especially if they are drug abusers with previous PCP. 
Introduction 
Recurrent bacterial pneumonia has recently been 
included among the clinical criteria for acquired 
immunodeficiency syndrome (AIDS), since bacterial 
pneumonia rates are significantly higher in patients 
with AIDS and they are often associated with the 
advanced stage of immunodepression (1). 
Although Staphylococcus aweus has been recog- 
nized as the most frequency cause of bacteraemia in 
HIV-infected patients (2-4), it has not been indicated 
previously as a frequent cause of pneumonia (5-8). 
However, the real incidence of S. aureus pneumonia 
(SAP) in HIV-infected patients still remains un- 
defined. In fact, many individuals may develop 
SAP before their HIV status is known and, in 
addition, patients with known HIV infection and 
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respiratory syndrome often take trimethoprim- 
sulphamethoxazole (as a prophylaxis or therapeuti- 
cally) for presumed or proven Pneumocystis carinii 
pneumonia (PCP), which makes aetiologic diagnosis 
of bacterial pneumonia difficult (6,8). The results 
of prospective cohort studies are not yet available, 
but it is possible to speculate that trimethoprim- 
sulphamethoxazole therapy for presumed or proven 
PCP can reduce the rate of SAP in AIDS patients. At 
present, there is only one report (9) of SAP in 
HIV-infected patients which demonstrates that this 
infection often occurs in patients with other pulmon- 
ary diseases (PCP and Kaposi’s sarcoma), and that it 
is associated with a significant mortality. In this study 
(9), however, the risk factors for SAP have not 
been detailed, and the analysis of the parameters 
influencing the mortality have not been included. 
The objectives of the present study were to better 
characterize the frequency, the risk factors and 
the clinical features of SAP associated with HIV 
infection, and the effect of these parameters on the 
disease outcome. 
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Patients and Methods 
A retrospective case-control study was conducted 
in the Department of Infectious Diseases of the 
Catholic University in Rome, Italy, considering all 
hospital admissions of HIV-infected patients from 1 
January 1986 to 31 December 1994. Medical records 
were reviewed for information on demographic fea- 
tures, i.e. age, sex, site of acquisition of pneumonia 
(community or hospital), HIV risk behaviour, nu- 
tritional status, AIDS-related conditions, interval 
from the diagnosis of AIDS, risk factors and clinical 
presentation of SAP, arterial blood gases level, 
number mm - 3 of circulating polymorphonuclear 
cells (PMN) and of T CD4+ cells, radiological find- 
ings, anti-microbial therapy and outcome of pneumo- 
nia. The following pneumonia risk factors were 
analysed: neutropenia, previous episodes of pneumo- 
nia, chronic lung diseases, smoke habits, alcoholism, 
cirrhosis, diabetes, chronic renal failure, neoplastic 
diseases, corticosteroid therapy and usage of a cen- 
tral venous catheter (CVC). A patient was considered 
as a smoker if he/she smoked more than 10 packs- 
year - i. Neutropenia was defined as an absolute 
neutrophil count less than 1000 mmp3. 
The diagnosis of bacterial pneumonia was consid- 
ered if a bacteria (other than Mycobacteria) was 
isolated from a specimen of sputum representative of 
the lower airways (i.e. 2 25 polymorphonuclear cells 
and _< 10 epithelial cells per 100 x microscopic field) 
and/or from bronchoalveolar lavage (BAL) and/or 
from blood, in patients with parenchymal infiltrates 
on chest X-ray and respiratory symptoms, i.e. cough 
with/without expectoration and/or chest pain. If 
another possible cause of pneumonia was present at 
the same time as SAP, the patient in question was not 
included in the study. Community-acquired pneu- 
monia was defined as an infection which occurred in 
a patient who had not been hospitalized within the I 
days preceding the onset of pulmonary symptoms. 
Nosocomial pneumonia was defined as an infection 
which occurred at least 72 h after hospital admission 
or occurred in a patient who had been hospitalized in 
the previous 2 weeks. A recurrence of pneumonia was 
considered if a new episode of SAP occurred after 
recovery from the first episode. 
The attack rate for S. aureus pulmonary infection 
was calculated as the number of episodes of SAP 
associated with HIV infection, divided by the total 
number of HIV-related hospital admissions x 1000. 
For the case-control study, each case was paired 
with two unmatched controls, selected at random 
from the same ward as the cases during the study 
period. These controls were HIV-infected patients 
without pneumonia and without sign of staphylo- 
coccal infection. The variables determined to be 
either present or absent in each case were also 
recorded for each control. The day of selection of 
the control was the cut-off date for determining the 
presence or absence of the variables. 
STATISTICAL ANALYSIS 
Quantitative variables were tested for normal dis- 
tribution and compared using Student’s two-tailed 
t-test. Differences in group proportions were assessed 
using X2-test or, for small numbers, using Fisher’s 
exact test. Potential risk and prognostic factors for 
pneumonia were analysed by univariate methods to 
screen (if a factor was significant) for inclusion in a 
multivariate model. For the analysis of the indicators 
of prognosis, the variable with the lowest death rate 
was given a relative odds ratio (OR) of 1 and this was 
later used as a reference category. Multivariate analy- 
sis was performed with a logistic regression model, 
and 95% test-based confidence intervals (CI) were 
used to determine the statistical significance of the 
OR. A stepward approach was used with 0.05 as a 
limit for entering new terms. All variables were 
entered in the logistic regression as categoric vari- 
ables with two categories (O=absent or normal; 
1 =present or abnormal). For those variables with 
more than two categories, a cut-off point was selected 
according to the results of the univariate analysis. 
Two-tailed tests of significance at the PcO.05 level 
were used to determine statistical significance. 
Results 
In the study period, 154 episodes of bacterial 
pneumonia were observed in 136 patients. Staphylo- 
coccus aureus pneumonia was diagnosed in 24 epi- 
sodes of pneumonia (16%) which occurred in 19 
patients. Staphylococcus aweus was also isolated in 
association with Streptococcus pneumoniae (three 
patients), Pseudomonas aeruginosa (two patients) and 
Enterobacter faecium (one patient). These patients 
were, however, excluded from the study. The attack 
rate for SAP was 8.31 per 1000 patients in the 2887 
HIV-related hospital admissions observed in the 
study period. The rate of SAP in the total yearly 
HIV-related admission increased progressively and is 
now 1.2% without substantial fluctuations from 1990. 
Patients were followed for an average of 16 months 
(range l-42, median 11 months). Thirteen patients 
(68%) were male and six patients were female (32%); 
their ages ranged from 18 to 67 years (mean age: 
35 * 9 years). Risk factors for HIV were: IVDA 
(84%), homosexual (10%) and heterosexual (6%) 
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contacts. According to the 1992 CDC AIDS defini- 
tion (1) five patients were in the B3 (26%) and 14 
patients were in the C3 (74%) category. The recur- 
rence of SAP was an AIDS-defining condition in 
one patient alone. The patients in the C3 category 
were diagnosed with AIDS O&48 months (median 
27 f 5 months) prior to the onset of SAP. The 
mean T CD4+ cell count was 40 mm- 3 (range 
1-167 mm - ‘) and the mean PMN cell number was 
2550 Vmrn3 (range 47339400 Vme3). The infection 
was community acquired in 13 cases (68%) and 
nosocomial in six cases (32%). For the characteristics 
of the patients, see Table 1. 
RISK FACTORS 
Univariate analysis identified three risk factors 
significantly associated with SAP: (1) IVDA (P=O.O2 
vs. control group, OR=4.80); (2) history of previous 
PCP (P=O.O3, OR=4.95); and (3) cirrhosis (P=O.O3, 
OR=6.60) (see Table 2). 
On the contrary, no statistically significant re- 
lationship was found between SAP and the following 
parameters: age, sex, HIV risk behaviour (other than 
IVDA), AIDS-related conditions, time from AIDS 
diagnosis, nutritional status, cigarette smoking, al- 
coholism, diabetes, previous episode of pneumonia 
(with the exception of PCP), presence of chronic 
pulmonary diseases, chronic renal failure, neoplastic 
diseases, use of corticosteroids, CVC, neutropenia 
and low T CD4+ cells (~50 mm-‘). 
The results of the Poisson model revealed that 
IVDA (P=O.O2) and previous PCP (P=O.O3) were the 
sole independent risk factors for the development 
of SAP. No other variables or interactions were 
statistically significant. 
MICROBIOLOGICAL DATA 
Staphylococcus aureus was isolated from sputum in 
15 patients (79%) (two or more samples) and from 
BAL in seven patients (37%). In 10 patients (53%) 
blood cultures were positive for S. aureus. In one 
patient, trans-thoracic needle aspiration of a lung 
abscess yielded pure growth of S. aureus, and in 
one additional patient, S. aureus was isolated from 
pleural fluid. 
The analysis of the antibiotic in vitro susceptibility 
of the S. aureus isolates showed that the rate of 
penicillin-methicillin-resistant strains was 14%. No 
resistance to glycopeptides (vancomycin or teico- 
planin) was documented in any of the isolates. 
CLINICAL AND RADIOLOGICAL FINDINGS 
All patients presented with fever (range 37.6- 
4O.l”C) and had an acute or sub-acute presentation 
of the illness. The most common symptoms were 
productive cough (74%) shortness of breath (37%) 
and pleuritic chest pain (26%) (see Table 1). On 
physical examination, abnormal breath sounds were 
observed in all cases. The mean respiratory rate 
was 22 & 7 breaths min - ‘. The mean PaO, was 
71 & 12 mmHg. In particular, six patients (31%) were 
hypoxaemic with PaO, ~60 mmHg. 
The radiological findings of SAP included lobar 
consolidation (78%), predominantly in the lower 
lobes (67%), consolidation with cavitation (11%) and 
interstitial nodular infiltrates (llO%) (see Table 1). 
In two patients (11%) SAP was bilateral. Pleural 
effusion was present in six patients (31%), and 
empyema was present in one of these patients. One 
patient, with cavitation and pleural effusion, devel- 
oped pneumothorax and died after 72 h. There was 
no significant relationship between the presence of 
effusion and the number of affected lobes, or whether 
there was bilateral vs. monolateral involvement. 
None of the patients with positive blood cultures 
had echocardiographic evidence of right-sided endo- 
carditis, and six active intravenous drug abusers, in 
whom pulmonary scintigraphy was performed, had 
no evidence of pulmonary embolisms. 
OUTCOME 
All patients were treated with antibiotic therapy 
which consisted of intravenous penicillinase-resistant 
p lactams or glycopeptides given for a mean of 14.3 
days. The response to therapy was favourable in 
84% of the patients. Three patients (16%) died with 
SAP as a direct or contributing cause of the death. 
In five patients (26%), SAP recurred within 2-6 
months. Using the univariate analysis, the following 
factors were significantly associated with higher 
mortality: (1) recurrence (P=O,Ol, OR= 18) and (2) 
low TCD4+ cells level (~50mrn-~) (P=O.O3, 
OR= 14.6). However, sex, age, chronic lung diseases, 
AIDS-related conditions, clinical and radiological 
findings, and neutropenia were not significantly 
associated with a higher fatality rate. The multi- 
variate analysis indicated that the low T CD4+ cell 
number (C 50 mm - 3, was the only independent risk 
factor for mortality (P= 0.02, OR= 13.4). 
Discussion 
Staphylococcus aureus is responsible for serious 
pulmonary infections in immunocompetent subjects 
(range l-10% for community-acquired; about 10% 
for nosocomial pneumonia) (10,ll). The first and 
largest study on SAP in adults was published by 
Chickering and Park in 1919, in the wake of the 1918 
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Table 2 Significant risk factors for the development of Staphylococcus aureus pneumonia 
(SAP) in HIV-infected patients 
Patients with SAP Control group 
n= 19 (%) n=38 (%) P OR (95% CI) 
Univariate analysis 
IVDA 16 (84) 20 (53) 0.02 4.80 (1.04-24.8) 
Past PCP 7 (37) 4 (11) 0.03 4.95 (1.03-X.2) 
Cirrhosis 5 (26) 2 (5) 0.03 6.60 (0.95-32.9) 
Multivariate analysis 
IVDA 0.02 5.50 (1~0618~2) 
Past PCP O-03 4.50 (1.0416) 
IVDA, intravenous drug abuse; PCP, Pneumocystis carinii pneumonia; OR, odds ratio; 
CI, confidence interval. 
Table 3 Significant prognostic factors of Staphylococcus aI*reus pneumonia (SAP) 
Patients died 
with SAP P (95$RcI) 
Univariate analysis 
Relapse 
Low T CD4+ cells (~50 mn-3) 
Multivariate analysis 
Low T CD4+ cells (450 mm-3) 
417 0.03 14.6 (0.0841) 
617 0.01 18 (1.00-59.2) 
0.02 13.4 (1.09-25.5) 
OR, odds ratio; CI, confidence interval. 
influenza epidemic (12). Subsequent studies have 
defined that SAP tends to occur in older patients with 
concomitant diseases (except during an influenza 
epidemic, when a higher percentage of young subjects 
can be infected), in post-operative status, in intensive 
care units or in mid-length hospitalization (13,14). 
Intravenous drug addiction is also considered to be a 
SAP risk factor (15). 
In HIV-infected patients, S. aureus has been 
reported as the most common cause of bacteraemia 
(2-4) and, less frequently, as a cause of pulmonary 
infections (5-8). Although a deficit in T CD4+ cells is 
the most relevant immunological alteration in AIDS 
patients, quantitative or qualitative deficits of poly- 
morphonuclear cells have also been documented in 
these patients (16,17), and they seem to be relevant 
for the development of S. aureus infections (18). In 
particular, it has been reported that neutrophils from 
homosexuals with AIDS have a defect (not related to 
abnormal chemotaxis) in their ability to the in vitro 
killing of 5’. aureus compared to normal subjects, and 
this may contribute to the development of S. aureus 
infections (19). 
In the present study, SAP occurred in a frequency 
exceeding that observed in the general population 
(lo), with a significative increase in the last few years. 
In two-thirds of patients, S. aureus pulmonary 
infection was community acquired, contrary to 
reports of immunocompetent patients in whom noso- 
comial origin of SAP is more common (11). How- 
ever, both these results can be related to the high 
number of intravenous drug abusers in these patients. 
Even though the predisposing factors of SAP in 
immunocompetent hosts are well defined (13,14), 
at present no statistical studies have detailed the 
predictors of SAP in HIV-infected patients. 
In the present series of patients, IVDA, previous 
PCP and cirrhosis were significant risk factors for the 
development of SAP. In particular, intravenous drug 
abusers represent the more relevant HIV-risk group 
with staphylococcal pneumonia. The specific risk for 
this infection is the result of endogenous and exogen- 
ous factors: malnutrition, poor personal hygiene and 
the recurrent exposure to bacterial agents, including 
S. aureus. In fact, this micro-organism can not only 
contaminate the skin but it is also present in greater 
numbers in the nose and throat of intravenous drug 
abusers than in the general population (20). Interest- 
ingly, the cultures of street heroin and injection 
needles have not revealed the presence of S. aureus 
(21). However, the real impact of intravenous drug 
abuse on the development of SAP is difficult to be 
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quantified since the large majority of the present 
patients, and of the Italian HIV-infected patients in 
general, are intravenous drug abusers (22). 
Previous observations (9,23) have indicated that 
other lung diseases, in particular Kaposi’s sarcoma 
and PCP, are highly associated with SAP. In the 
present patients, pulmonary Kaposi’s sarcoma was 
not a significant risk condition, while previous epi- 
sodes of PCP significantly increased the risk for the 
development of SAP. This is probably related to the 
superinfection by S. aureus of the cysts or pneu- 
matoceles that are frequently present in the lung after 
recovery from PCP (24). Alternatively, it is also poss- 
ible that P. car&ii may damage the bronchial mucosal 
integrity, predisposing the patients to S. aureus in- 
fection. In addition, patients with previous episodes 
of PCP usually have a low number of T CD4+ cells 
and also present with alterations of other defence 
mechanisms, which favours the development of 
bacterial pneumonia (24). Patients with cirrhosis, in 
particular alcoholic cirrhosis, are more likely to de- 
velop bacterial pneumonia as a result of the decreased 
resistance to infections (25), often consequent to defi- 
cits of neutrophil function, impaired complement 
response, defective mobility to opsonize bacteria and 
impaired reticula-endothelial function (26). More- 
over, chronic hepatitis and cirrhosis are frequently 
observed in IVDA patients; the group of HIV 
patients most commonly presenting with SAP. 
Although the concomitant effect of these risk 
factors can be responsible for the high number of 
SAP observed in HIV-infected patients, multivariate 
analysis indicated that IVDA and previous PCP were 
the sole independent risk factors associated with the 
development of SAP. 
The clinical and radiological characteristics of 
S. aureuz pulmonary infection in the present series of 
patients are similar to those reported previously in 
non-AIDS patients (IO), with the exception of the 
blood cultures which were positive in about half 
of the patients. This percentage, higher than that 
reported in HIV-seronegative patients (13,14), in- 
directly supports the possible haematogenous spread 
of S. aureus infection in many of the present patients, 
a significant number of whom were intravenous drug 
abusers. Against this possibility, however, is the 
observation that in patients with SAP and positive 
blood cultures, the clinical presentation, radiological 
(including pulmonary scintigraphy) and echocardio- 
graphic findings were more likely to be indicative of a 
primary, rather than a secondary to haematogenous 
spread, pneumonia and that none of these patients 
had evidence of right-sided endocarditis signs or 
pulmonary embolisms. 
Since the recovery of S. aureus from sputum has a 
low specificity, it was only considered to be indicative 
of an aetiologic role for pneumonia if two or more 
positive samples were obtained without the presence 
of other possible aetiologic agents. Moreover, since 
the response rate to anti-staphylococcal therapy 
observed in these patients was the same regardless of 
the source of isolation (blood, BAL or sputum), this 
result indirectly confirms the correct application of 
this diagnostic criteria. 
Chest X-ray generally showed typical lobar 
involvement (predominantly in lower lobes), which 
was frequently associated with pleural effusion and, 
in one patient only, with pulmonary abscess. This last 
finding, in contrast to what is often observed in 
immunocompetent subjects (27), can be related to the 
quantitative and qualitative deficits of neutrophils 
which are observed frequently in AIDS patients 
(16,17). It is noteworthy that in a few patients in 
whom interstitial nodular infiltrates were observed, 
the BAL was used to discriminate from other 
aetiologic causes of pulmonary infections and, in 
particular, P. carinii and Mycobacteria. 
In the authors’ experience, the outcome of SAP 
treated with specific anti-staphylococcal therapy was 
favourable in the majority of patients. This contrasts 
with the high mortality (30-50%) of S. aureus pulmon- 
ary infection reported in HIV-seronegative patients 
that developed pneumonia a few days after the onset 
of influenza (12). The authors suggest, on a purely 
speculative ground, that the relatively low number of 
penicillin-resistant S. aureus isolates associated with 
an early diagnosis and treatment of patients (other- 
wise in follow-up for HIV infection) influenced the 
prognosis positively. The percentage of recurrence, 
difficult to compare with other studies since 5’. aureus 
pneumonia is not always clearly sorted from other 
types of pneumonia, is probably the consequence of 
the severe immunodeficiency even though it is difficult 
to exclude the role of an early interruption of the 
therapy for the low compliance of some patients, 
especially in drug abusers. 
The univariate analysis revealed that the low level 
of circulating T CD4+ cells (~50 mm - 3, and the 
occurrence of relapse influenced the prognosis nega- 
tively, but only the low number of T CD4+ cells was, 
on multivariate analysis, an independent prognostic 
factor. This indicates that the profound immuno- 
deficiency observed in patients with advanced AIDS 
is the most important factor influencing the survival 
of patients with SAP. 
In conclusion, this study emphasizes the emerging 
importance of S. aureus as aetiologic agent of pul- 
monary infections in patients with AIDS. Although 
Predictors of S. aureus pneumonia associated with HIV infection 537 
other micro-organisms, such as S. pneumoniae and 
Haemophilus inzuenzae, which are frequent causes of 
bacterial pneumonia in HIV-infected patients (7), 
may present the same clinical picture, an acute pres- 
entation with lobar involvement and pleural effusion 
on chest X-ray should be evaluated carefully for 
the possibility of SAP in HIV-infected patients, 
especially in intravenous drug abusers and those with 
previous PCP. 
Acknowledgement 
The authors are indebted to their colleagues at the 
Departments of Microbiology and Radiology of 
the Catholic University Hospital for their helpful 
support. 
References 
1. Centers for Diseases Control. 1992 revised classification 
system for HIV infection and expanded surveillance 
case definition for AIDS among adolescent and adults. 
MMWR 1992; 4147. 
2. Shanson DC. Septicaemia in patients with AIDS. Trans 
R Sot Trop Med Hyg 1990; 84 (Suppl. 1): 14-16. 
3. Jacobson MA. Gellermann H, Chambers H. Stanhvlo- 
coccus aureus’bacteremia and’recurrent staphyloco&al 
infection in patients with acquired immunodeficiency 
syndrome and AIDS related complex. Am J Med 1988; 
85: 172-176. 
4. Tumbarello M, Tacconelli E, Caponera S, Cauda R, 
Ortona L. The impact of bacteremia on HIV infection. 
Nine years experience in a large Italian university 
hospital. J Infect 1995; 31: 123-131. 
5. Polsky B, Gold JMW, Whimbey E et al. Bacterial 
pneumonia in patients with the acquired immuno- 
deficiency syndrome. Ann Intern Med 1986; 104: 3841. 
6. Murray JF, Garay SM, Hopewell PC et al. Pulmonary 
complications of the acquired immunodeficiency syn- 
drome: an update. Report of the Second National 
Heart, Lung and Blood Institute Workshop. Am Rev 
Respiv Dis 1987; 135: 504509. 
7. Caiaffa WT, Graham NMH, Vlahov D. Bacterial pneu- 
monia in adult populations with human immuno- 
deficiency virus (HIV) infection. Am J Epidemiol 1993; 
138: 909-922. 
8. Chaisson RE. Bacterial pneumonia in patients with 
human immunodeficiency virus infection. Semin Resp 
Infect 1989; 4: 133-138. 
9. Levine SJ, White DA, Fels AO. The incidence and 
significance of Staphylococcus aureuf in respiratory 
cultures from patients infected with the human 
immunodeficiency virus. Am Rev Respir Dis 1990; 141: 
89-93. 
10. Kaye MG, Fox MJ, Bartlett JG, Braman SS, Glassroth 
J. The clinical spectrum of Staphylococcus aureus 
oulmonarv infection. Chest 1990; 97, 788-792. 
11. Musher DM, Franc0 M. Staphylococcal pneumonia: a 
new perspective. Chest 1981; 79: 1722173. 
12. Chickering HT, Park JH. Staphylococcus aweus 
pneumonia. JAMA 1919; 72: 617-626. 
13. Woodhead MA, Radvan J, MacFarlane JT. Adult 
community-acquired staphylococcal pneumonia in the 
antibiotic era: a review of 61 cases. Q J Med 1987; 64: 
783-790. 
14. Watakunakorn C. Bacteremic Staphylococcus aweus 
pneumonia. Stand J Infect Dis 1987; 19: 623-627. 
15. Berman DS, Schaefler S, Simberkoff MS, Rahal JJ. 
Staphylococcus aureus colonisation in intravenous drug 
abusers, dialysis patients and diabetics. J Infect Dis 
1987; 155: 829-832. 
16. Nielsen H, Kharazmi A, Faber V. Blood monocyte and 
neutrophil function in the acquired immune deficiency 
syndrome. Scund J Immunol 1986; 24: 291-296. 
17. Mertins SD, Cauda R. The role of polymorphonuclear 
leukocytes in infection by retrovirus with emphasis on 
the human immunodeficiency virus. Viral Immunol 
1990; 3: 173-177. 
18. Murphy PM, Lane HC, Gallin JI, Fauci AS. Marked 
disparity in incidence of bacterial infections in patients 
with acquired immunodeficiency syndrome receiving 
interleukin-2 or interferon gamma. Ann Intern Med 
1988; 62: 136142. 
19. Valone FH, Payon DG, Abrams DI, Goetzl EJ. Defec- 
tive polymorphonuclear leukocyte chemotaxis in homo- 
sexual men with persistent lymphonode syndrome. 
J Infect Dis 1984; 150: 267-271. 
20. Weike T, Schiller R, Rehrenbach FJ, Pohle HD. Associ- 
ation between Staphylococcus aureus nasopharingeal 
colonisation and bacteremia in patients infected 
with the human immunodeficiency virus. Eur J Clin 
Microbial Infect Dis 1992; 11: 985-989. 
21. Tuazon CU. The microbiological study of street heroin 
and injection paraphernalia. J Infect Dis 1974; 129: 
327-329. 
22. Commissione Nazionale per la Lotta Contro 1’AIDS. 
Aggiornamento dei Casi di AIDS Notificati in Italia al 
31 Dicembre 1994, 1994, pp. l-20. 
23. Whimbey E, Gold JWM, Polsky B et al. Bacteremia 
and fungemia in patients with the acquired immuno- 
deficiency syndrome. Ann Intern Med 1986; 104: 511- 
514. 
24. Dohn MN, Frame PT. Clinical manifestation in adults. 
In: Walzer PD, ed. Pneumocystis carinii Pneumonia, 
1994, pp. 331-359. 
25. Wyke RJ. Problems of bacterial infection in patient 
with liver disease. Gut 1987; 28: 623. 
‘26. Akalin HE, Lalei Y, Telatar H. Bactericidal and 
opsonic activity of ascitic fluid from cirrhotic and 
non-cirrhotic patients. J Infect Dis 1983; 147: loll- 
1013. 
